Medical condition
Dlbcl
Dlbcl is a medical condition tracked by NovaPharmaNews across 10 associated drugs and ongoing industry coverage. Explore approved and pipeline therapies, regulatory status, and the latest developments.
Associated drugs & therapies
- odronextamab (ORDSPONO) Nervous system (NOT)
- rituximab (RIXIMYO) Antineoplastic and immunomodulating agents (L01)
- epcoritamab (EPKINLY) Antineoplastic and immunomodulating agents (L01)
- glofitamab (COLUMVI) Antineoplastic and immunomodulating agents (L01)
- lisocabtagene maraleucel (BREYANZI) Antineoplastic and immunomodulating agents (L01)
- loncastuximab tesirine (ZYNLONTA) Antineoplastic and immunomodulating agents (L01)
- polatuzumab vedotin (POLIVY) Antineoplastic and immunomodulating agents (L01)
- tafasitamab (MINJUVI) Antineoplastic and immunomodulating agents (L01)
- tisagenlecleucel (KYMRIAH) Antineoplastic and immunomodulating agents (L01)
- axicabtagene ciloleucel (YESCARTA) Antineoplastic and immunomodulating agents (L01)